
Opinion|Videos|June 17, 2024
INAVO120: Inavolisib Combination Therapy in PIK3CA-Mutated Breast Cancer
Medical oncologists discuss the INAVO120 study, which is evaluating inavolisib combination therapy in patients with PIK3CA-mutated breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5











































